No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Nephrol Dial Transplant 22(4):1150-5 (2007) PMID 17255126
Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated with an increased risk of hyperkalaemia. However, few studies have investigated the effect of RAS blockades on serum potassium in dialysis patients.
DOI: 10.1093/ndt/gfl752
Version: za2963e q8za2 q8zb7 q8zc4 q8zd6 q8ze3 q8zf1 q8zg2